Evidence map›Paper›PMID 25773485›Full record

ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2015

Filtration markers as predictors of ESRD and mortality in Southwestern American Indians with type 2 diabetes.

Meredith C Foster, Lesley A Inker, Chi-Yuan Hsu, John H Eckfeldt, Andrew S Levey, Meda E Pavkov, Bryan D Myers, Peter H Bennett, Paul L Kimmel, Ramachandran S Vasan and 3 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed, 3 pooled it
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 3 syntheses or guidelines pooled it, 55 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Filtration Markers as Predictors of ESRD and Mortality: Individual Participant Data Meta-Analysis.Clinical journal of the American Society of Nephrology : CJASN · 2017
    Pooled it
  4. Trial
  5. Filtration Markers, Cardiovascular Disease, Mortality, and Kidney Outcomes in Stable Kidney Transplant Recipients: The FAVORIT Trial.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2017
    Trial
  6. Article
  7. Review
  8. Article
  9. GFR estimated with creatinine rather than cystatin C is more reflective of the true risk of adverse outcomes with low GFR in kidney transplant recipients.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association · 2023
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Molecular Mechanisms of Diabetic Kidney Disease.International journal of molecular sciences · 2022
    Review
  15. Review
  16. A New Panel-Estimated GFR, Including βAmerican journal of kidney diseases : the official journal of the National Kidney Foundation · 2021
    Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 1 country.

Meredith C FosterTufts Medical Center, Boston, MA.
Lesley A InkerTufts Medical Center, Boston, MA.
Chi-Yuan HsuUniversity of California, San Francisco, San Francisco, CA.
John H EckfeldtUniversity of Minnesota, Minneapolis, MN.
Andrew S LeveyTufts Medical Center, Boston, MA.
Meda E PavkovCenters for Disease Control and Prevention, Atlanta, GA.
Bryan D MyersStanford University, Stanford, CA.
Peter H BennettNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ.
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD.
Ramachandran S VasanBoston University, Boston, MA.
Josef CoreshJohns Hopkins Bloomberg School of Public Health, Baltimore, MD.
Robert G NelsonNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ. Electronic address: rnelson@nih.gov.
CKD Biomarkers Consortium
Tufts Medical Center · USNational Institute of Diabetes and Digestive and Kidney Diseases · USCenters for Disease Control and Prevention · USJohns Hopkins University · USStanford University · USUniversity of California, San Francisco · USUniversity of Minnesota · US

Funding

Institute for Clinical and Translational ResearchUL1TR001079 · NCATS · JOHNS HOPKINS UNIVERSITY · PI FORD, DANIEL ERNEST · 2013 to 2017
$60.1M
CARDIOVASCULAR EPIDEMIOLOGY INSTITUTIONAL TRAININGT32HL007024 · NHLBI · JOHNS HOPKINS UNIVERSITY · PI Elizabeth Selvin · 1985 to 2026
$17.5M
Epidemiology, Pathophysiology and Treatment of Diabetic NephropathyZIADK069062 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI NELSON, ROBERT G · 2009 to 2023
$10.1M
Proteomic Approach to CKD Biomarker Discovery and ValidationU01DK085689 · NIDDK · JOHNS HOPKINS UNIVERSITY · PI CORESH, JOSEF · 2009 to 2019
$5.6M
Urinary Biomarkers of Chronic Kidney Disease Pathology and ProgressionU01DK085660 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI BONVENTRE, JOSEPH VINCENT, WAIKAR, SUSHRUT S. · 2009 to 2019
$5.3M
"Validation of Novel CKD Biomarkers in CRIC"U01DK085649 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HSU, CHI-YUAN, LIU, KATHLEEN D · 2009 to 2013
$4.4M
The New York CKD Biomarker Discovery ProgramU01DK085688 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BOTTINGER, ERWIN P. · 2009 to 2013
$3.0M
Urinary Biomarkers in Biopsy Defined Early Nephropathy in Types 1 and 2 DiabetesU01DK085651 · NIDDK · UNIVERSITY OF MINNESOTA · PI MAUER, S. MICHAEL · 2009 to 2013
$2.2M
Forecasters of futute and progressive CDK in patients with microvascular glomerulU01DK085673 · NIDDK · OHIO STATE UNIVERSITY · PI KLEIN, JON, ROVIN, BRAD H · 2009 to 2013
$2.0M
Macrovascular and Other Complications Of Type 2 Diabetes MellitusZ01DK069036 · NIDDK · NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES · PI KNOWLER, WILLIAM C · 1990 to 2008
$552k
Intramural NIH HHS Z01 DK069036NCATS NIH HHS UL1 TR001079NHLBI NIH HHS T32 HL007024NIDDK NIH HHS U01 DK085649NIDDK NIH HHS U01 DK085651NIDDK NIH HHS U01DK085651NIDDK NIH HHS U01 DK085660NIDDK NIH HHS U01DK085660NIDDK NIH HHS U01 DK085673NIDDK NIH HHS U01DK085673NIDDK NIH HHS U01 DK085688NIDDK NIH HHS U01DK085688NIDDK NIH HHS U01 DK085689NIDDK NIH HHS U01DK085689NIDDK NIH HHS U01DK85649
6 · The paper itself

Abstract

backgroundA growing number of serum filtration markers are associated with mortality and end-stage renal disease (ESRD) in adults. Whether β-trace protein (BTP) and β2-microglobulin (B2M) are associated with these outcomes in adults with type 2 diabetes is not known. STUDY

designLongitudinal cohort study. SETTING &

participants250 Pima Indians with type 2 diabetes (69% women; mean age, 42 years; mean diabetes duration, 11 years). PREDICTORS: Serum BTP, B2M, and glomerular filtration rate measured by iothalamate clearance (mGFR) or estimated using creatinine (eGFRcr) or cystatin C level (eGFRcys). OUTCOMES & MEASUREMENTS: Incident ESRD and all-cause mortality through December 2013. HRs were reported per interquartile range decrease of the inverse of BTP and B2M (1/BTP and 1/B2M) using Cox regression. Improvement in risk prediction with the addition of BTP or B2M level to established markers (eGFRcys with mGFR or eGFRcr) was evaluated using C statistics, continuous net reclassification improvement, and relative integrated discrimination improvement (RIDI).

resultsDuring a median follow-up of 14 years, 69 participants developed ESRD and 95 died. Both novel markers were associated with ESRD in multivariable models. BTP level remained statistically significant after further adjustment for mGFR (1/BTP, 1.53 [95% CI, 1.01-2.30]; 1/B2M, 1.54 [95% CI, 0.98-2.42]). B2M level was associated with mortality in multivariable models and after further adjustment for mGFR (HR, 2.12; 95% CI, 1.38-3.26). The addition of B2M level to established markers increased the C statistic for mortality but only weakly when assessed by either continuous net reclassification improvement or RIDI; none was improved for ESRD by the addition of these markers. LIMITATIONS: Small sample size, single measurements of markers.

conclusionsIn Pima Indians with type 2 diabetes, BTP and, to a lesser extent, B2M levels were associated with ESRD. B2M level was associated with mortality after adjustment for traditional risk factors and established filtration markers. Further studies are warranted to confirm whether inclusion of B2M level in a multimarker approach leads to improved risk prediction for mortality in this population.

Indexed as

Indians, North AmericanAdultArizonabeta 2-MicroglobulinBiomarkersComorbidityDiabetes Mellitus, Type 2Diabetic NephropathiesDisease ProgressionDisease SusceptibilityEthnicityFemaleFollow-Up StudiesGlomerular Filtration RateHumansHyperlipidemiasbeta 2-MicroglobulinBiomarkersIntramolecular OxidoreductasesLipocalinsprostaglandin R2 D-isomerasebeta-2 microglobulin (B2M)Beta-trace protein (BTP)CKD Biomarkers Consortiumdiabetic kidney failureend-stage renal disease (ESRD)filtration markersglomerular filtration rate (GFR)kidney functionmortalityPima Indianstype 2 diabetes mellitus

Identifiers

PMID25773485
PMCPMC4485524
OpenAlexW1967154137

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.